William Blank is the Founding Partner and Portfolio Manager of Squadron Capital Management (“SCM”), a firm dedicated to investing in publicly traded micro- to mid-cap therapeutics companies. With deep expertise in therapeutic development and equity capital markets, SCM employs a thorough, repeatable diligence process, enabled by its bespoke analytics and idea generation platform, in order to capitalize on inefficiencies within the public therapeutics sector. This approach aims to generate high absolute returns for investors, independent of sector-specific or macroeconomic conditions.
Previously, as Principal at Aspire Capital from 2010 to 2022, Mr. Blank focused on a similar investment universe of micro- to mid-cap therapeutics companies. He led scientific, clinical, regulatory, and financial due diligence efforts while managing a team of seven research professionals. Over his twelve-year tenure, Mr. Blank gained significant transactional experience, participating in more than 200 biotech-related equity capital market offerings. He also co-developed and managed a therapeutics equity research externship program, training over 50 life sciences PhD candidates and post-docs from the University of Chicago, University of Illinois, and Northwestern University.
Mr. Blank began his career in biotechnology at Integrated Genomics, Inc., conducting antimicrobial drug target discovery research and supporting business development efforts targeting major pharmaceutical and biotechnology companies. He holds a B.S. in Molecular and Cellular Biology from the University of Illinois and an M.S. in Biotechnology from Johns Hopkins University. Mr. Blank also holds the Chartered Financial Analyst (CFA) designation and is a member of the CFA Society of Chicago.
